Preliminary study on serum microRNA expression profile in patients with diabetic retinopathy

doi:10.3877/cma.j.issn.2095-2007.2019.04.009

Abstract

Abstract:

Objective

The aim of this study was to study the feasibility of serum microRNA(miRNA) as a novel biomarker in patients with diabetic retinopathy(DR).

Methods

This was a cohort study. From November 2014 to June 2015, 69 patients were enrolled in Ophthalmology Department and Endocrinology Department of Shengjing Hospital, China Medical University. 30 simple diabetes mellitus(DM) patients were divided into DM group, and 39 diabetic retinopathy(DR) patients were divided into DR group. Randomly selected 3 patients from each group, and used the miRNA microarray technology to detected the expression level of serum miRNA.The hierarchical cluster analysis was used to obtain the serum miRNA expression profile of DR patients. Bioinformatics methods was used to analyze the target genes and related signaling pathways of the specific expression of serum miRNA. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) technology was used to detect the expression of miRNA in serum of the two patients. To establish the receiver operating characteristic(ROC) curve, to evaluate the diagnostic efficacy of specific miRNA in the serum of DR patients.

Results

miRNA microarray showed that in 3100 kinds of mature miRNAs, a total of 19 miRNA with significance differences were screened. Of the difference miRNA, there were 13 upregulated miRNAs, while there were 6 downregulated miRNAs. The results suggestted tha there were specific miRNA expression in tthe serum of DR patients. The qRT-PCR showed that the expression of miR-19b, miR-221 and miR-18b were significantly increased in DR group, and the difference were statistically significant (U=256.027, 125.515, 254.017; P<0.05), and in consistent with miRNA microarray screening results. The ROC curves showed that miR-19b(AUC=0.78, 95%CI=0.66-0.90), miR-221(AUC=0.89, 95%CI=0.81-0.97) and miR-18b (AUC=0.78, 95%CI=0.67-0.90) all had diagnostic efficacy for DR, and miR-221 was the most effective one.

Conclusions

The serum of patients with DR exist specific miRNA expression profiles, and these specific miRNAs may as a regulator by adjusting target gene to regulate the occurrence and development of DR. Of all the specific miRNAs markets, miR-221 may themost expective one.

Key words: Diabetic retinopathy, MicroRNA, Expression profile

Haisheng Yu, Henan Liu, Xiaolong Chen, Na Wu. Preliminary study on serum microRNA expression profile in patients with diabetic retinopathy[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2019, 09(04): 246-251.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2019.04.009

https://zhykyxzz.cma-cmc.com.cn/EN/Y2019/V09/I04/246

Figures/Tables 4

References 40

[1]	Cheung N, Mitchell P, Wong TY. Diabetic retinopathy[J]. Lancet, 2010, 376(9735): 124-136.
[2]	Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy[J]. N Engl J Med, 2012, 366(13): 1227-1239.
[3]	Cheung N, Wong TY. Diabetic retinopathy and systemic vascular complications[J]. Prog Retin Eye Res, 2008, 27(2): 161-176.
[4]	Tang J, Kern TS. Inflammation in diabetic retinopathy[J]. Prog Retin Eye Res, 2011, 30(5): 343-358.
[5]	Cunha-Vaz J, Ribeiro L, Lobo C. Phenotypes and biomarkers of diabetic retinopathy[J]. Prog Retin Eye Res, 2014, 41: 90-111.
[6]	Mastropasqua R, Toto L, Cipollone F, et al. Role of microRNAs in the modulation of diabetic retinopathy[J]. Prog Retin Eye Res, 2014, 43: 92-107.
[7]	Simó R, Hernández C. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence[J]. Prog Retin Eye Res, 2015, 48: 160-180.
[8]	Kowluru RA, Kowluru A, Mishra M, et al. Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy[J]. Prog Retin Eye Res, 2015, 48: 40-61.
[9]	Stitt AW, Curtis TM, Chen M, et al. The progress in understanding and treatment of diabetic retinopathy[J]. Prog Retin Eye Res, 2016, 51: 156-186.
[10]	Benfey PN. Molecular biology: microRNA is here to stay[J]. Nature, 2003, 425(6955): 244-245.
[11]	Chien HY, Lee TP, Chen CY, et al. Circulating microRNA as a diagnostic marker in populations with type 2 diabetes mellitus and diabetic complications[J]. J Chin Med Assoc, 2015, 78(4): 204-211.
[12]	American Diabetes Association. Diagnosis and classification of diabetes mellitus[J]. Diabetes Care, 2014, 37(Suppl 1): S81-S90.
[13]	Wilkinson CP, Ferris FL, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales[J]. Ophthalmology, 2003, 110(9): 1677-1682.
[14]	Klein BE. Reduction in risk of progression of diabetic retinopathy[J]. N Engl J Med, 2010, 363(3): 287-288.
[15]	Aiello LP. Angiogenic pathways in diabetic retinopathy[J]. N Engl J Med, 2005, 353(8): 839-841.
[16]	Roy S, Bae E, Amin S, et al. Extracellular matrix, gap junctions, and retinal vascular homeostasis in diabetic retinopathy[J]. Exp Eye Res, 2015, 133: 58-68.
[17]	Reiter CE, Gardner TW. Functions of insulin and insulin receptor signaling in retina: possible implications for diabetic retinopathy[J]. Prog Retin Eye Res, 2003, 22(4): 545-562.
[18]	Simó R, Sundstrom JM, Antonetti DA. Ocular Anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy[J]. Diabetes Care, 2014, 37: 893-899.
[19]	Cheung N, Wong IY, Wong TY. Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications[J]. Diabetes Care, 2014, 37(4): 900-905.
[20]	Williams M, Hogg RE, Chakravarthy U. Antioxidants and diabetic retinopathy[J]. Curr Diab Rep, 2013, 13(4): 481-487.
[21]	Behl T, Kaur I, Kotwani A. Implication of oxidative stress in progression of diabetic retinopathy[J]. Surv Ophthalmol, 2016, 61(2): 187-196.
[22]	Zhang W, Liu H, Rojas M, et al. Anti-inflammatory therapy for diabetic retinopathy[J]. Immunotherapy, 2011, 3(5): 609-628.
[23]	Durham JT, Herman IM. Microvascular modifications in diabetic retinopathy[J]. Curr Diab Rep, 2011, 11(4): 253-264.
[24]	Zhang L, Chen B, Tang L. Metabolic memory: mechanisms and implications for diabetic retinopathy[J]. Diabetes Res Clin Pract, 2012, 96(3): 286-293.
[25]	Kowluru RA. Mitochondria damage in the pathogenesis of diabetic retinopathy and in the metabolic memory associated with its continued progression[J]. Curr Med Chem, 2013, 20(26): 3226-3233.
[26]	Frank RN. Diabetic retinopathy[J]. N Engl J Med, 2004, 350(1): 48-58.
[27]	Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review[J]. JAMA, 2007, 298(8): 902-916.
[28]	Einarsdóttir AB, Stefánsson E. Prevention of diabetic retinopathy[J]. Lancet, 2009, 373(9672): 1316-1318.
[29]	Ockrim Z, Yorston D. Managing diabetic retinopathy[J]. BMJ, 2010, 341: c5400.
[30]	Cech TR, Steitz JA. The noncoding RNA revolution-trashing old rules to forge new ones[J]. Cell, 2014, 157(1): 77-94.
[31]	Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease[J]. Cell, 2012, 148(6): 1172-1187.
[32]	Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281-297.
[33]	Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics[J]. J Cell Physiol, 2016, 231(1): 25-30.
[34]	Suárez Y, Fernández-Hernando C, Yu J, et al. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis[J]. Proc Natl Acad Sci U S A, 2008, 105(37): 14082-14087.
[35]	Kovacs B, Lumayag S, Cowan C, et al. MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats[J]. Invest Ophthalmol Vis Sci, 2011, 52(7): 4402-4409.
[36]	Wu JH, Gao Y, Ren AJ, et al. Altered microRNA expression profiles in retinas with diabetic retinopathy[J]. Ophthalmic Res, 2012, 47(4): 195-201.
[37]	Wang C, Wang S, Zhao P, et al. MiR-221 promotes cardiac hypertrophy in vitro through the modulation of p27 expression[J]. J Cell Biochem, 2012, 113(6): 2040-2046.
[38]	Dai R, Li J, Liu Y, et al. miR-221/222 suppression protects against endoplasmic reticulum stress-induced apoptosis via p27(Kip1)- and MEK/ERK-mediated cell cycle regulation[J]. Biol Chem, 2010, 391(7): 791-801.
[39]	Kedde M, van Kouwenhove M, Zwart W, et al. A Pumilio-induced RNA structure switch in p27-3′ UTR controls miR-221 and miR-222 accessibility[J]. Nat Cell Biol, 2010, 12(10): 1014-1020.
[40]	Lolli A, Lambertini E, Penolazzi L, et al. Pro-chondrogenic effect of miR-221 and slug depletion in human MSCs[J]. Stem Cell Rev, 2014, 10(6): 841-855.

组别	例数	空腹血糖(mmol/l)	餐后2 h血糖(mmol/l)	糖化血红蛋白(%)
DR组	39	7.8±0.6	12.7±0.8	7.8±0.9
糖尿病组	30	7.6±0.5	12.4±1.0	7.5±0.8
t值		1.127	1.263	1.631
P值		>0.05	>0.05	>0.05

组别	例数	空腹血糖(mmol/l)	餐后2 h血糖(mmol/l)	糖化血红蛋白(%)
DR组	39	7.8±0.6	12.7±0.8	7.8±0.9
糖尿病组	30	7.6±0.5	12.4±1.0	7.5±0.8
t值		1.127	1.263	1.631
P值		>0.05	>0.05	>0.05

Please choose a citation manager

Content to export